Lipid Nanoparticle Manufacturing Market Report and Forecast 2025-2034
Description
The global lipid nanoparticle manufacturing market was valued at USD 880.00 Million in 2024 driven by the advancements in mRNA therapeutics, innovations in drug delivery systems across the globe. It is expected to grow at a CAGR of 11.00% during the forecast period of 2025-2034 and attain a market value of USD 2498.69 Million by 2034.
Lipid Nanoparticle Manufacturing Market Overview
Lipid nanoparticles (LNPs) are advanced non-viral delivery systems essential for mRNA therapeutics, gene editing, and targeted drug delivery. Growth drivers in the market include advancements in mRNA vaccines and therapeutics, increasing investments in rare disease treatments, and growing investments in the biopharma sector. Trends such as improved brain-targeting LNPs and enhanced delivery technologies are reshaping the market landscape. These innovations, combined with rising demand, position the market for significant growth in precision medicine in the coming years.
Lipid Nanoparticle Manufacturing Market Growth Drivers
Advancements in mRNA Therapeutics and Vaccines Drives Market Growth
Advancements in mRNA therapeutics and vaccines, particularly the success of lipid nanoparticle-mRNA vaccines against COVID-19, are significantly driving market growth for lipid nanoparticles. Lipid nanoparticles (LNPs) are the most advanced non-viral platforms for mRNA delivery, pivotal in the success of mRNA COVID-19 vaccines. Their safety, stability, and delivery efficiency drive ongoing developments in infectious disease treatments, cancer therapies, protein replacement, and genome editing. This success showcases their critical role as non-viral delivery systems, enhancing mRNA stability and efficacy. As pharmaceutical companies increasingly invest in lipid nanoparticle formulations for applications in infectious diseases, cancer therapies, and gene editing, the rising demand for these innovative delivery mechanisms is expected to propel the market in the forecast period.
Lipid Nanoparticle Manufacturing Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Rise in Manufacturing of Lipid Nanoparticles
The market is evolving rapidly, driven by innovations that enhance therapeutic delivery systems. For instance, in December 2024, researchers at the University of Pennsylvania developed advanced LNPs capable of crossing the blood-brain barrier and specifically targeting neurons and endothelial cells. This development incorporates peptides for precise mRNA delivery, a critical advancement for therapies targeting neurological diseases such as Alzheimer's and Parkinson's. As LNPs continue to prove their efficacy in specialized applications, the market is poised for growth, with increasing demand for targeted drug delivery systems in the biopharmaceutical sector.
Rise in Strategic Mergers and Acquisitions to Affect the Lipid Nanoparticle Manufacturing Market Landscape Significantly
The surge in strategic mergers and acquisitions is poised to significantly impact the market landscape. As companies seek to enhance their capabilities and expand their product offerings, these strategic moves facilitate innovation and growth within the sector. For instance, in August 2024, VION Biosciences acquired Echelon Biosciences. This acquisition aimed to bolster VION's portfolio in life sciences, particularly in mRNA technology and lipid nanoparticles for drug manufacturing. Following VION's 2023 Aldon acquisition, the integration of Echelon underscores a focused approach to addressing niche areas in biopharmaceutical research. By operating as a subsidiary, Echelon retained its leadership while leveraging VION’s resources to advance scientific discovery and broaden its market presence. Such strategic acquisitions illustrate a robust trend that will likely propel the lipid nanoparticle market forward, positioning companies to better meet the growing demand for innovative therapeutic solutions.
Growing Investments in Biopharma to Meet Rising Lipid Nanoparticle Manufacturing Market Demand
Growing investments in biopharma are significantly accelerating the demand for lipid nanoparticle manufacturing. For instance, in June 2024, Agilent Technologies strengthened its position in the biopharma sector by investing USD 925 million in Biovectra, a Canadian CDMO. Biovectra is anticipated to witness growth, strengthening Agilent's capabilities in plasmid DNA and mRNA technologies. By integrating Biovectra into its diagnostics and genomics group, Agilent enhances its biopharma offerings and expands advanced manufacturing facilities, catering to the evolving needs of major pharmaceutical players.
Enhancing mRNA Delivery to Boost Lipid Nanoparticle Manufacturing Market
Advancements in mRNA delivery systems are poised to drive substantial growth in the market. In July 2024, AmplifyBio announced a strategic partnership with AvaBurg LLC to enhance LNP formulations for mRNA delivery. With expertise in lipid formulation, stability, and regulatory compliance, this collaboration aimed to bolster AmplifyBio’s ongoing efforts, following their collaboration with RNAV8 Bio, thereby improving manufacturing capabilities at their center.
Lipid Nanoparticle Manufacturing Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product
Market Share by Molecule Set to Witness Significant Growth
Based on molecules, the market is divided into siRNA, mRNA, and Others. Among these, the mRNA molecule is expected to dominate the market, primarily driven by the successful deployment of mRNA vaccines during the pandemic. This sector is poised for significant growth, as ongoing research expands the potential applications of mRNA beyond infectious diseases into areas such as oncology and rare genetic disorders. Additionally, advancements in delivery mechanisms and increased investment in mRNA technology are expected to fuel demand. As more mRNA-based products receive regulatory approvals and clinical trials expand, this segment is likely to catalyze overall market growth, positioning itself as a crucial player in the evolving landscape of precision medicine.
Lipid Nanoparticle Manufacturing Market Analysis by Region
Based on region, the market report covers North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Among these, North America is expected to dominate the market due to the rising number of drug development projects, the presence of a well-established healthcare market, significant spending on R&D activities, and the presence of key manufacturing are the key factors that contribute to market growth in North America.
Leading Players in Lipid Nanoparticle Manufacturing Market
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Avanti Polar Lipids, Inc.
Established in 1967 and headquartered in Alabaster, Alabama, Avanti Polar Lipids specializes in high-purity lipids for research and pharmaceutical development. Their product portfolio includes a wide range of phospholipids, sphingolipids, and sterols, essential for lipid nanoparticle formulations used in drug delivery systems.
Merck KGaA
Founded in 1668 and based in Germany, Merck KGaA offers a comprehensive range of lipids and related products through its life science division. Their portfolio includes high-purity lipids and lipid derivatives utilized in the formulation of lipid nanoparticles for various therapeutic applications.
Evonik Industries AG
Established in 2007 with headquarters in Germany, Evonik Industries provides advanced lipid-based formulations for drug delivery. Their product line features a variety of lipids and lipid-based excipients designed for the development of lipid nanoparticles, enhancing the delivery and efficacy of pharmaceutical compounds.
FUJIFILM Pharmaceuticals Inc.
Founded in 1934 and headquartered in Tokyo, Japan, FUJIFILM Pharmaceuticals focuses on the development of innovative drug delivery systems. The company offers lipid-based formulations and technologies aimed at improving the stability and delivery of therapeutic agents, including those utilizing lipid nanoparticle systems.
Other companies include Nippon Fine Chemical, Recipharm AB, Emergent BioSolutions, Inc., EUROAPI SA, Corden Pharma International GmbH, Cayman Chemical Company, Precision NanoSystems Inc., and NOF Corporation.
Key Questions Answered in the Global Lipid Nanoparticle Manufacturing Market
Lipid Nanoparticle Manufacturing Market Overview
Lipid nanoparticles (LNPs) are advanced non-viral delivery systems essential for mRNA therapeutics, gene editing, and targeted drug delivery. Growth drivers in the market include advancements in mRNA vaccines and therapeutics, increasing investments in rare disease treatments, and growing investments in the biopharma sector. Trends such as improved brain-targeting LNPs and enhanced delivery technologies are reshaping the market landscape. These innovations, combined with rising demand, position the market for significant growth in precision medicine in the coming years.
Lipid Nanoparticle Manufacturing Market Growth Drivers
Advancements in mRNA Therapeutics and Vaccines Drives Market Growth
Advancements in mRNA therapeutics and vaccines, particularly the success of lipid nanoparticle-mRNA vaccines against COVID-19, are significantly driving market growth for lipid nanoparticles. Lipid nanoparticles (LNPs) are the most advanced non-viral platforms for mRNA delivery, pivotal in the success of mRNA COVID-19 vaccines. Their safety, stability, and delivery efficiency drive ongoing developments in infectious disease treatments, cancer therapies, protein replacement, and genome editing. This success showcases their critical role as non-viral delivery systems, enhancing mRNA stability and efficacy. As pharmaceutical companies increasingly invest in lipid nanoparticle formulations for applications in infectious diseases, cancer therapies, and gene editing, the rising demand for these innovative delivery mechanisms is expected to propel the market in the forecast period.
Lipid Nanoparticle Manufacturing Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Rise in Manufacturing of Lipid Nanoparticles
The market is evolving rapidly, driven by innovations that enhance therapeutic delivery systems. For instance, in December 2024, researchers at the University of Pennsylvania developed advanced LNPs capable of crossing the blood-brain barrier and specifically targeting neurons and endothelial cells. This development incorporates peptides for precise mRNA delivery, a critical advancement for therapies targeting neurological diseases such as Alzheimer's and Parkinson's. As LNPs continue to prove their efficacy in specialized applications, the market is poised for growth, with increasing demand for targeted drug delivery systems in the biopharmaceutical sector.
Rise in Strategic Mergers and Acquisitions to Affect the Lipid Nanoparticle Manufacturing Market Landscape Significantly
The surge in strategic mergers and acquisitions is poised to significantly impact the market landscape. As companies seek to enhance their capabilities and expand their product offerings, these strategic moves facilitate innovation and growth within the sector. For instance, in August 2024, VION Biosciences acquired Echelon Biosciences. This acquisition aimed to bolster VION's portfolio in life sciences, particularly in mRNA technology and lipid nanoparticles for drug manufacturing. Following VION's 2023 Aldon acquisition, the integration of Echelon underscores a focused approach to addressing niche areas in biopharmaceutical research. By operating as a subsidiary, Echelon retained its leadership while leveraging VION’s resources to advance scientific discovery and broaden its market presence. Such strategic acquisitions illustrate a robust trend that will likely propel the lipid nanoparticle market forward, positioning companies to better meet the growing demand for innovative therapeutic solutions.
Growing Investments in Biopharma to Meet Rising Lipid Nanoparticle Manufacturing Market Demand
Growing investments in biopharma are significantly accelerating the demand for lipid nanoparticle manufacturing. For instance, in June 2024, Agilent Technologies strengthened its position in the biopharma sector by investing USD 925 million in Biovectra, a Canadian CDMO. Biovectra is anticipated to witness growth, strengthening Agilent's capabilities in plasmid DNA and mRNA technologies. By integrating Biovectra into its diagnostics and genomics group, Agilent enhances its biopharma offerings and expands advanced manufacturing facilities, catering to the evolving needs of major pharmaceutical players.
Enhancing mRNA Delivery to Boost Lipid Nanoparticle Manufacturing Market
Advancements in mRNA delivery systems are poised to drive substantial growth in the market. In July 2024, AmplifyBio announced a strategic partnership with AvaBurg LLC to enhance LNP formulations for mRNA delivery. With expertise in lipid formulation, stability, and regulatory compliance, this collaboration aimed to bolster AmplifyBio’s ongoing efforts, following their collaboration with RNAV8 Bio, thereby improving manufacturing capabilities at their center.
Lipid Nanoparticle Manufacturing Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product
- Ionizable Lipids
- Pegylated Lipids
- Neutral Lipids
- Phospholipids
- Others
- Solid Lipid Nanoparticles (SLNs)
- Nanostructured Lipid Carriers (NLCs)
- Others
- siRNA
- mRNA
- Others
- Commercial
- Polyneuropathy
- Covid-19
- Clinical
- Covid-19
- Cancer
- Others
- Pharmaceutical Companies
- Biotechnology Companies
- Academic and Research Institutes
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Market Share by Molecule Set to Witness Significant Growth
Based on molecules, the market is divided into siRNA, mRNA, and Others. Among these, the mRNA molecule is expected to dominate the market, primarily driven by the successful deployment of mRNA vaccines during the pandemic. This sector is poised for significant growth, as ongoing research expands the potential applications of mRNA beyond infectious diseases into areas such as oncology and rare genetic disorders. Additionally, advancements in delivery mechanisms and increased investment in mRNA technology are expected to fuel demand. As more mRNA-based products receive regulatory approvals and clinical trials expand, this segment is likely to catalyze overall market growth, positioning itself as a crucial player in the evolving landscape of precision medicine.
Lipid Nanoparticle Manufacturing Market Analysis by Region
Based on region, the market report covers North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Among these, North America is expected to dominate the market due to the rising number of drug development projects, the presence of a well-established healthcare market, significant spending on R&D activities, and the presence of key manufacturing are the key factors that contribute to market growth in North America.
Leading Players in Lipid Nanoparticle Manufacturing Market
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Avanti Polar Lipids, Inc.
Established in 1967 and headquartered in Alabaster, Alabama, Avanti Polar Lipids specializes in high-purity lipids for research and pharmaceutical development. Their product portfolio includes a wide range of phospholipids, sphingolipids, and sterols, essential for lipid nanoparticle formulations used in drug delivery systems.
Merck KGaA
Founded in 1668 and based in Germany, Merck KGaA offers a comprehensive range of lipids and related products through its life science division. Their portfolio includes high-purity lipids and lipid derivatives utilized in the formulation of lipid nanoparticles for various therapeutic applications.
Evonik Industries AG
Established in 2007 with headquarters in Germany, Evonik Industries provides advanced lipid-based formulations for drug delivery. Their product line features a variety of lipids and lipid-based excipients designed for the development of lipid nanoparticles, enhancing the delivery and efficacy of pharmaceutical compounds.
FUJIFILM Pharmaceuticals Inc.
Founded in 1934 and headquartered in Tokyo, Japan, FUJIFILM Pharmaceuticals focuses on the development of innovative drug delivery systems. The company offers lipid-based formulations and technologies aimed at improving the stability and delivery of therapeutic agents, including those utilizing lipid nanoparticle systems.
Other companies include Nippon Fine Chemical, Recipharm AB, Emergent BioSolutions, Inc., EUROAPI SA, Corden Pharma International GmbH, Cayman Chemical Company, Precision NanoSystems Inc., and NOF Corporation.
Key Questions Answered in the Global Lipid Nanoparticle Manufacturing Market
- What was the global lipid nanoparticle manufacturing market value in 2024?
- What is the global lipid nanoparticle manufacturing market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on the product?
- What is the market breakup based on the LNP type?
- What is the market segmentation based on the molecule?
- What is the market breakup based on the application?
- What is the market segmentation based on the end user?
- What are the major factors aiding the global lipid nanoparticle manufacturing market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major global lipid nanoparticle manufacturing market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the global lipid nanoparticle manufacturing market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Lipid Nanoparticle Manufacturing Market Overview
- 3.1 Global Lipid Nanoparticle Manufacturing Market Historical Value (2018-2024)
- 3.2 Global Lipid Nanoparticle Manufacturing Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Lipid Nanoparticle Manufacturing Market Landscape*
- 5.1 Global Lipid Nanoparticle Manufacturing Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Lipid Nanoparticle Manufacturing Market: Product Landscape
- 5.2.1 Analysis By Product
- 5.2.2 Analysis By Molecule
- 6 Global Lipid Nanoparticle Manufacturing Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Lipid Nanoparticle Manufacturing Market Segmentation (218-2034)
- 7.1 Global Lipid Nanoparticle Manufacturing Market (2018-2034) by Product
- 7.1.1 Market Overview
- 7.1.2 Ionizable lipids
- 7.1.3 PEGylated lipids
- 7.1.4 Neutral lipids
- 7.1.5 Phospholipids
- 7.1.6 Others
- 7.2 Global Lipid Nanoparticle Manufacturing Market (2018-2034) by LNP Type
- 7.2.1 Market Overview
- 7.2.2 Solid lipid Nanoparticles (SLNs)
- 7.2.3 Nanostructured lipid Carriers (NLCs)
- 7.2.4 Others
- 7.3 Global Lipid Nanoparticle Manufacturing Market (2018-2034) by Molecule
- 7.3.1 Market Overview
- 7.3.2 siRNA
- 7.3.3 mRNA
- 7.3.4 Others
- 7.4 Global Lipid Nanoparticle Manufacturing Market (2018-2034) by Application
- 7.4.1 Market Overview
- 7.4.2 Commercial
- 7.4.2.1 Polyneuropathy
- 7.4.2.2 Covid-19
- 7.4.3 Clinical
- 7.4.3.1 Covid-19
- 7.4.3.2 Cancer
- 7.4.3.3 Others
- 7.5 Global Lipid Nanoparticle Manufacturing Market (2018-2034) by End User
- 7.5.1 Market Overview
- 7.5.2 Pharmaceutical Companies
- 7.5.3 Biotechnology Companies
- 7.5.4 Academic & Research Institutes
- 7.6 Global Lipid Nanoparticle Manufacturing Market (2018-2034) by Region
- 7.6.1 Market Overview
- 7.6.2 North America
- 7.6.3 Europe
- 7.6.4 Asia Pacific
- 7.6.5 Latin America
- 7.6.6 Middle East and Africa
- 8 North America Lipid Nanoparticle Manufacturing Market (218-2034)
- 8.1 North America Lipid Nanoparticle Manufacturing Market (2018-2034) by Product
- 8.1.1 Market Overview
- 8.1.2 Ionizable lipids
- 8.1.3 PEGylated lipids
- 8.1.4 Neutral lipids
- 8.1.5 Phospholipids
- 8.1.6 Others
- 8.2 North America Lipid Nanoparticle Manufacturing Market (2018-2034) by LNP Type
- 8.2.1 Market Overview
- 8.2.2 Solid lipid Nanoparticles (SLNs)
- 8.2.3 Nanostructured lipid Carriers (NLCs)
- 8.2.4 Others
- 8.3 North America Lipid Nanoparticle Manufacturing Market (2018-2034) by Molecule
- 8.3.1 Market Overview
- 8.3.2 siRNA
- 8.3.3 mRNA
- 8.3.4 Others
- 8.4 North America Lipid Nanoparticle Manufacturing Market (2018-2034) by Application
- 8.4.1 Market Overview
- 8.4.2 Commercial
- 8.4.2.1 Polyneuropathy
- 8.4.2.2 Covid-19
- 8.4.3 Clinical
- 8.4.3.1 Covid-19
- 8.4.3.2 Cancer
- 8.4.3.3 Others
- 8.5 North America Lipid Nanoparticle Manufacturing Market (2018-2034) by End User
- 8.5.1 Market Overview
- 8.5.2 Pharmaceutical Companies
- 8.5.3 Biotechnology Companies
- 8.5.4 Academic & Research Institutes
- 8.6 North America Lipid Nanoparticle Manufacturing Market (2018-2034) by Country
- 8.6.1 United States of America
- 8.6.1.1 United States of America Lipid Nanoparticle Manufacturing Market Size, by Product
- 8.6.2 Canada
- 8.6.2.1 Canada Lipid Nanoparticle Manufacturing Market Size, by Product
- 9 Europe Lipid Nanoparticle Manufacturing Market (218-2034)
- 9.1 Europe Lipid Nanoparticle Manufacturing Market (2018-2034) by Product
- 9.1.1 Market Overview
- 9.1.2 Ionizable lipids
- 9.1.3 PEGylated lipids
- 9.1.4 Neutral lipids
- 9.1.5 Phospholipids
- 9.1.6 Others
- 9.2 Europe Lipid Nanoparticle Manufacturing Market (2018-2034) by LNP Type
- 9.2.1 Market Overview
- 9.2.2 Solid lipid Nanoparticles (SLNs)
- 9.2.3 Nanostructured lipid Carriers (NLCs)
- 9.2.4 Others
- 9.3 Europe Lipid Nanoparticle Manufacturing Market (2018-2034) by Molecule
- 9.3.1 Market Overview
- 9.3.2 siRNA
- 9.3.3 mRNA
- 9.3.4 Others
- 9.4 Europe Lipid Nanoparticle Manufacturing Market (2018-2034) by Application
- 9.4.1 Market Overview
- 9.4.2 Commercial
- 9.4.2.1 Polyneuropathy
- 9.4.2.2 Covid-19
- 9.4.3 Clinical
- 9.4.3.1 Covid-19
- 9.4.3.2 Cancer
- 9.4.3.3 Others
- 9.5 Europe Lipid Nanoparticle Manufacturing Market (2018-2034) by End User
- 9.5.1 Market Overview
- 9.5.2 Pharmaceutical Companies
- 9.5.3 Biotechnology Companies
- 9.5.4 Academic & Research Institutes
- 9.6 Europe Lipid Nanoparticle Manufacturing Market (2018-2034) by Country
- 9.6.1 United Kingdom
- 9.6.1.1 United Kingdom Lipid Nanoparticle Manufacturing Market Size, by Product
- 9.6.2 Germany
- 9.6.2.1 Germany Lipid Nanoparticle Manufacturing Market Size, by Product
- 9.6.3 France
- 9.6.3.1 France Lipid Nanoparticle Manufacturing Market Size, by Product
- 9.6.4 Italy
- 9.6.4.1 Italy Lipid Nanoparticle Manufacturing Market Size, by Product
- 9.6.5 Others
- 10 Asia Pacific Lipid Nanoparticle Manufacturing Market (218-2034)
- 10.1 Asia Pacific Lipid Nanoparticle Manufacturing Market (2018-2034) by Product
- 10.1.1 Market Overview
- 10.1.2 Ionizable lipids
- 10.1.3 PEGylated lipids
- 10.1.4 Neutral lipids
- 10.1.5 Phospholipids
- 10.1.6 Others
- 10.2 Asia Pacific Lipid Nanoparticle Manufacturing Market (2018-2034) by LNP Type
- 10.2.1 Market Overview
- 10.2.2 Solid lipid Nanoparticles (SLNs)
- 10.2.3 Nanostructured lipid Carriers (NLCs)
- 10.2.4 Others
- 10.3 Asia Pacific Lipid Nanoparticle Manufacturing Market (2018-2034) by Molecule
- 10.3.1 Market Overview
- 10.3.2 siRNA
- 10.3.3 mRNA
- 10.3.4 Others
- 10.4 Asia Pacific Lipid Nanoparticle Manufacturing Market (2018-2034) by Application
- 10.4.1 Market Overview
- 10.4.2 Commercial
- 10.4.2.1 Polyneuropathy
- 10.4.2.2 Covid-19
- 10.4.3 Clinical
- 10.4.3.1 Covid-19
- 10.4.3.2 Cancer
- 10.4.3.3 Others
- 10.5 Asia Pacific Lipid Nanoparticle Manufacturing Market (2018-2034) by End User
- 10.5.1 Market Overview
- 10.5.2 Pharmaceutical Companies
- 10.5.3 Biotechnology Companies
- 10.5.4 Academic & Research Institutes
- 10.6 Asia Pacific Lipid Nanoparticle Manufacturing Market (2018-2034) by Country
- 10.6.1 China
- 10.6.1.1 China Lipid Nanoparticle Manufacturing Market Size, by Product
- 10.6.2 Japan
- 10.6.2.1 Japan Lipid Nanoparticle Manufacturing Market Size, by Product
- 10.6.3 India
- 10.6.3.1 India Lipid Nanoparticle Manufacturing Market Size, by Product
- 10.6.4 ASEAN
- 10.6.4.1 ASEAN Lipid Nanoparticle Manufacturing Market Size, by Product
- 10.6.5 Australia
- 10.6.5.1 Australia Lipid Nanoparticle Manufacturing Market Size, by Product
- 10.6.6 Others
- 11 Latin America Lipid Nanoparticle Manufacturing Market (218-2034)
- 11.1 Latin America Lipid Nanoparticle Manufacturing Market (2018-2034) by Product
- 11.1.1 Market Overview
- 11.1.2 Ionizable lipids
- 11.1.3 PEGylated lipids
- 11.1.4 Neutral lipids
- 11.1.5 Phospholipids
- 11.1.6 Others
- 11.2 Latin America Lipid Nanoparticle Manufacturing Market (2018-2034) by LNP Type
- 11.2.1 Market Overview
- 11.2.2 Solid lipid Nanoparticles (SLNs)
- 11.2.3 Nanostructured lipid Carriers (NLCs)
- 11.2.4 Others
- 11.3 Latin America Lipid Nanoparticle Manufacturing Market (2018-2034) by Molecule
- 11.3.1 Market Overview
- 11.3.2 siRNA
- 11.3.3 mRNA
- 11.3.4 Others
- 11.4 Latin America Lipid Nanoparticle Manufacturing Market (2018-2034) by Application
- 11.4.1 Market Overview
- 11.4.2 Commercial
- 11.4.2.1 Polyneuropathy
- 11.4.2.2 Covid-19
- 11.4.3 Clinical
- 11.4.3.1 Covid-19
- 11.4.3.2 Cancer
- 11.4.3.3 Others
- 11.5 Latin America Lipid Nanoparticle Manufacturing Market (2018-2034) by End User
- 11.5.1 Market Overview
- 11.5.2 Pharmaceutical Companies
- 11.5.3 Biotechnology Companies
- 11.5.4 Academic & Research Institutes
- 11.6 Latin America Lipid Nanoparticle Manufacturing Market (2018-2034) by Country
- 11.6.1 Brazil
- 11.6.1.1 Brazil Lipid Nanoparticle Manufacturing Market Size, by Product
- 11.6.2 Argentina
- 11.6.2.1 Argentina Lipid Nanoparticle Manufacturing Market Size, by Product
- 11.6.3 Mexico
- 11.6.3.1 Mexico Lipid Nanoparticle Manufacturing Market Size, by Product
- 11.6.4 Others
- 12 Middle East and Africa Lipid Nanoparticle Manufacturing Market (218-2034)
- 12.1 Middle East and Africa Lipid Nanoparticle Manufacturing Market (2018-2034) by Product
- 12.1.1 Market Overview
- 12.1.2 Ionizable lipids
- 12.1.3 PEGylated lipids
- 12.1.4 Neutral lipids
- 12.1.5 Phospholipids
- 12.1.6 Others
- 12.2 Middle East and Africa Lipid Nanoparticle Manufacturing Market (2018-2034) by LNP Type
- 12.2.1 Market Overview
- 12.2.2 Solid lipid Nanoparticles (SLNs)
- 12.2.3 Nanostructured lipid Carriers (NLCs)
- 12.2.4 Others
- 12.3 Middle East and Africa Lipid Nanoparticle Manufacturing Market (2018-2034) by Molecule
- 12.3.1 Market Overview
- 12.3.2 siRNA
- 12.3.3 mRNA
- 12.3.4 Others
- 12.4 Middle East and Africa Lipid Nanoparticle Manufacturing Market (2018-2034) by Application
- 12.4.1 Market Overview
- 12.4.2 Commercial
- 12.4.2.1 Polyneuropathy
- 12.4.2.2 Covid-19
- 12.4.3 Clinical
- 12.4.3.1 Covid-19
- 12.4.3.2 Cancer
- 12.4.3.3 Others
- 12.5 Middle East and Africa Lipid Nanoparticle Manufacturing Market (2018-2034) by End User
- 12.5.1 Market Overview
- 12.5.2 Pharmaceutical Companies
- 12.5.3 Biotechnology Companies
- 12.5.4 Academic & Research Institutes
- 12.6 Middle East and Africa Lipid Nanoparticle Manufacturing Market (2018-2034) by Country
- 12.6.1 Saudi Arabia
- 12.6.1.1 Saudi Arabia Lipid Nanoparticle Manufacturing Market Size, by Product
- 12.6.2 United Arab Emirates
- 12.6.2.1 United Arab Emirates Lipid Nanoparticle Manufacturing Market Size, by Product
- 12.6.3 Nigeria
- 12.6.3.1 Nigeria Lipid Nanoparticle Manufacturing Market Size, by Product
- 12.6.4 South Africa
- 12.6.4.1 South Africa Lipid Nanoparticle Manufacturing Market Size, by Product
- 12.6.5 Others
- 13 Regulatory Framework
- 13.1 Regulatory Overview
- 13.2 US FDA
- 13.3 EU EMA
- 13.4 INDIA CDSCO
- 13.5 JAPAN PMDA
- 13.6 Others
- 14 Patent Analysis
- 14.1 Analysis By Product of Patent
- 14.2 Analysis by Publication Year
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Patent Age
- 14.5 Analysis by CPC Analysis
- 14.6 Analysis by Patent Valuation
- 15 Grant Analysis
- 15.1 Analysis by Year
- 15.2 Analysis by Amount Awarded
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Grant Product
- 15.5 Analysis by Funding Institute
- 15.6 Analysis by Departments
- 15.7 Analysis by Recipient Organization
- 16 Funding and Investment Analysis
- 16.1 Analysis by Funding Instances
- 16.2 Analysis by Drug Class of Funding
- 16.3 Analysis by Funding Amount
- 16.4 Analysis by Leading Players
- 16.5 Analysis by Leading Investors
- 16.6 Analysis by Geography
- 17 Strategic Initiatives
- 17.1 Analysis by Partnership Instances
- 17.2 Analysis by Drug Class of Partnership
- 17.3 Analysis by Leading Players
- 17.4 Analysis by Geography
- 18 Supplier Landscape
- 18.1 Market Share Analysis, By Region (Top 5 Companies)
- 18.1.1 Market Share Analysis: Global
- 18.1.2 Market Share Analysis: North America
- 18.1.3 Market Share Analysis: Europe
- 18.1.4 Market Share Analysis: Asia Pacific
- 18.1.5 Market Share Analysis: Others
- 18.2 Avanti Polar Lipids, Inc.
- 18.2.1 Financial Analysis
- 18.2.2 Product Portfolio
- 18.2.3 Demographic Reach and Achievements
- 18.2.4 Company News and Development
- 18.2.5 Certifications
- 18.3 Merck KGaA
- 18.3.1 Financial Analysis
- 18.3.2 Product Portfolio
- 18.3.3 Demographic Reach and Achievements
- 18.3.4 Company News and Development
- 18.3.5 Certifications
- 18.4 Evonik Industries AG
- 18.4.1 Financial Analysis
- 18.4.2 Product Portfolio
- 18.4.3 Demographic Reach and Achievements
- 18.4.4 Company News and Development
- 18.4.5 Certifications
- 18.5 FUJIFILM Pharmaceuticals Inc.
- 18.5.1 Financial Analysis
- 18.5.2 Product Portfolio
- 18.5.3 Demographic Reach and Achievements
- 18.5.4 Company News and Development
- 18.5.5 Certifications
- 18.6 Nippon Fine Chemical
- 18.6.1 Financial Analysis
- 18.6.2 Product Portfolio
- 18.6.3 Demographic Reach and Achievements
- 18.6.4 Company News and Development
- 18.6.5 Certifications
- 18.7 Recipharm AB
- 18.7.1 Financial Analysis
- 18.7.2 Product Portfolio
- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Company News and Development
- 18.7.5 Certifications
- 18.8 Emergent BioSolutions, Inc.
- 18.8.1 Financial Analysis
- 18.8.2 Product Portfolio
- 18.8.3 Demographic Reach and Achievements
- 18.8.4 Company News and Development
- 18.8.5 Certifications
- 18.9 EUROAPI SA
- 18.9.1 Financial Analysis
- 18.9.2 Product Portfolio
- 18.9.3 Demographic Reach and Achievements
- 18.9.4 Company News and Development
- 18.9.5 Certifications
- 18.10 Corden Pharma International GmbH
- 18.10.1 Financial Analysis
- 18.10.2 Product Portfolio
- 18.10.3 Demographic Reach and Achievements
- 18.10.4 Company News and Development
- 18.10.5 Certifications
- 18.11 Cayman Chemical Company
- 18.11.1 Financial Analysis
- 18.11.2 Product Portfolio
- 18.11.3 Demographic Reach and Achievements
- 18.11.4 Company News and Development
- 18.11.5 Certifications
- 18.12 NOF Corporation
- 18.12.1 Financial Analysis
- 18.12.2 Product Portfolio
- 18.12.3 Demographic Reach and Achievements
- 18.12.4 Company News and Development
- 18.12.5 Certifications
- 18.13 Precision NanoSystems Inc.
- 18.13.1 Financial Analysis
- 18.13.2 Product Portfolio
- 18.13.3 Demographic Reach and Achievements
- 18.13.4 Company News and Development
- 18.13.5 Certifications
- 19 Global Lipid Nanoparticle Manufacturing Market – Distribution Model (Additional Insight)
- 19.1 Overview
- 19.2 Potential Distributors
- 19.3 Key Parameters for Distribution Partner Assessment
- 20 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
